Suzanne Lentzsch MD

Hematology•New York, NY

Hematologic Oncology

Professor of Medicine at CUMC, Director, Multiple Myeloma and Amyloidosis Program

Request appointment

622 W 168th StNew York, NY 10032
Book by Phone+1(448) 334-5338
Fax+1 212-305-6762

Overview of Dr. Lentzsch

Dr. Suzanne Lentzsch is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Lawrence Hospital. She received her medical degree from Humboldt University of Berlin - Charite Faculty of Medicine and has been in practice 36 years. Dr. Lentzsch accepts several types of health insurance, listed below. She is one of 82 doctors at New York-Presbyterian Hospital and one of 25 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. She has more than 100 publications and over 500 citings.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2001
Humboldt University School of MedicinePh.D, Cum Laude, 1990 - 1994
Humboldt University of Berlin - Charite Faculty of MedicineClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NY State Medical License 2011 - 2027
PA State Medical License 2006 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2014-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2014-2017

Clinical Trials

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
COMPLETED
PHASE2
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
TERMINATED
PHASE1
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Jan 01

Publications & Presentations

PubMed

Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.
Simon Zhen, Sorina Nicoleta Bandelita, Divaya Bhutani, Mathew S Maurer, Karan Wats
American Journal of Hematology. 2026-09-01
A Clinically Applicable Conversion Formula Between NT-proBNP and BNP in Light-Chain Amyloidosis.
Eli Muchtar, Allan S Jaffe, Andrew Staron, Vaishali Sanchorawala, Heather Landau
JACC. Cardiooncology. 2026-08-01
1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis.
Jing Fu, Michael S Hughes, Gavreel F Kalantarov, Huihui Ma, Shirong Li
Blood. 2026-07-29

Journal Articles

Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance
E Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
Selinexor plus Low-Dose Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Suzanne Lentzsch, Cristina Gasparetto, Blood
Beyond NEOD001 for Systemic Light-Chain Amyloidosis
Suzanne Lentzsch, Cindy Varga, Blood

Books/Book Chapters

Genetic and Molecular Epidemiology of Multiple Myeloma
Chapter: Cap-Dependent Protein Translation Initiation in Multiple Myeloma: An Attractive Target for Therapy
Lentzsch S, Fu J, Li SSpringer Science2013
Multiple Myeloma - A New Era of Treatment Strategies
Chapter: Management of Complications of Multiple Myeloma
Lentzsch SEditors: Podar K and Anderson KC.Bentham Science Publishers2011
Oxidative Stress in Cancer Biology Therapy
Chapter: Histone Deacetylase Inhibitors, Oxidative Stress, and Multiple Myeloma Therapy
Feng R, Lentzsch SEditors: Spitz Douglas, R.Springer Science, New York, NY2011

Abstracts/Posters

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance
Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Untangling Amyloidosis 2018
60th American Society of Hematology Annual Meeting - 11/30/2018
Bone Disease in Multiple Myeloma
ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/17/2018
What is Optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction
New York, NY - 1/1/2015

Other

Treatment Combination Offers New Option for Patients with Advanced Multiple Myeloma
Suzanne Lentzsch, UPMC Physician Resources
http://blogs.upmcphysicianresources.com/2011/treatment-combination-offers-new-option-for-patients-with-advanced-multiple-myeloma-upci-researchers-find/
Multiple Myeloma and Bone Disease
Suzanne Lentzsch, Wego Health
http://sharinghub.wegohealth.com/multiple-myeloma-and-your-bones/40-treating-multiple-myeloma-bone-disease
Managing Myeloma a Professional Resource for Multiple Myeloma
Suzanne Lentzsch
http://www.managingmyeloma.com/knowledge-center/clinical-trials/highlighted-trials-2013/804-phase-ii-trial-with-elotuzumab-plus-lenalidomide-and-low-dose-dexamethasone-in

Press Mentions

Journal of Clinical Oncology (JCO) PodcastJuly 28th, 2025
Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible PatientsJune 5th, 2025
Undetectable Disease Status in Myeloma Similar with Drug Therapy, TransplantationJune 3rd, 2025

Grant Support

CUIMC Calabresi Clinical Oncology Career Development ProgramCOLUMBIA UNIVERSITY HEALTH SCIENCES2024–2029
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple MyelomaCOLUMBIA UNIVERSITY HEALTH SCIENCES2021–2026
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple MyelomaCOLUMBIA UNIVERSITY HEALTH SCIENCES2021–2026

Insurance Accepted

CIGNA HMO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Healthfirst New York
HIP of New York - Select PPO
MagnaCare PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
Please verify your coverage with the provider's office directly when scheduling an appointment